Skip to main content

Table 2 Results of the two Phase III open-label clinical trials

From: MMV in partnership: the Eurartesim® experience

Study

PCR-corrected cure rate (mITT)

 

Eurartesim

AS+MQ

A+L

DM040010 (n=1087)

97.0%

95.3%

-

DM040011 (n=1524)

92.7%

-

94.8%

  1. A+L: artemether+lumefantrine; AS+MQ: artesunate+mefloquine; mITT:modified intention-to-treat (defined as all randomized patients whoreceived at least one dose of study treatment, with the exclusion ofthose patients lost to follow-up for unknown reasons); PCR:polymerase chain reaction.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us